AttendMe Owl Logo
AttendMe
Evidence Evolution
RheumatologyRheumatology

How This Evidence Evolved

Giant Cell Arteritis Management

From prolonged glucocorticoid dependence to IL-6 receptor blockade as steroid-sparing therapy

20.4

Timeline

Hunder Criteria
1990
TABUL
2016
GiACTA
2017
Abatacept GCA withdrawal
2017
GiACTA Extension
2021
Mavrilimumab GCA phase 2
2022
Sarilumab GCA phase 3
2023
EULAR recommendations for the use of imaging in large vessel vasculitis in clinical practice: 2023 update
2024
GCAptAIN
2026
2025 EULAR recommendations for the management of polymyalgia rheumatica and primary large vessel vasculitis
2026
Trial
Guideline
Approval
Meta-analysis
Signal

Early observations and pilot data that first suggested a new direction

The 1990 ACR classification criteria for giant cell arteritis (GCA) include age 50 or older at disease onset. GiACTA describes frequent relapse during glucocorticoid tapering and side effects with prolonged use. Its trial of the IL-6 receptor inhibitor tocilizumab addressed the need for sustained remission while reducing glucocorticoid exposure.
Proof

Landmark RCTs and pivotal trials that established the evidence base

GiACTA randomized 251 patients with GCA. Tocilizumab 162 mg weekly or every other week plus a 26-week prednisone taper achieved sustained glucocorticoid-free remission at week 52 in 56% and 53%, respectively. Placebo with 26-week or 52-week tapers achieved 14% and 18% (p<0.001 for each active-treatment comparison with placebo). Median cumulative prednisone doses over 52 weeks were 1,862 mg in each tocilizumab group versus 3,296 mg and 3,818 mg in the placebo groups. Longer follow-up was needed to assess durability and safety.
Extension

Follow-up studies, subgroup analyses, and real-world validation

In GiACTA's open-label extension, 25 of 59 patients (42%) who stopped weekly tocilizumab in remission at 1 year stayed in drug-free remission for 2 more years, and tocilizumab-based regimens restored remission after relapse. TABUL (381 patients) found ultrasound more sensitive than temporal artery biopsy for diagnosis (54% vs 39%) but less specific (81% vs 100%). A phase 3 sarilumab trial stopped early (83 of 360 planned patients): sustained remission at week 52 was 46% with sarilumab 200 mg vs 0% with placebo (26-week tapers), too few patients for clear conclusions.
Guidelines

Integration into clinical practice guidelines and recommendations

The 2025 EULAR recommendations advise adjunctive therapy for selected patients with GCA, using IL-6 receptor inhibitors or upadacitinib; methotrexate may be an alternative. GiACTA tested tocilizumab 162 mg subcutaneously weekly with a 26-week prednisone taper.
Now

Current standard of care and ongoing research directions

Published trials tested several steroid-sparing approaches in GCA. Abatacept withdrawal randomization found 12-month relapse-free survival of 48% versus 31% with placebo. Mavrilimumab reduced the hazard of flare through week 26 versus placebo (HR 0.38, 95% CI 0.15–0.92). In phase 3 GCAptAIN, secukinumab 300 mg with a 26-week taper did not significantly improve 52-week sustained remission versus placebo with a 52-week taper (25.6% vs 16.9%; P=.09). These results do not establish efficacy specifically after tocilizumab failure. Treatment duration, relapse prevention and disease-activity monitoring remain questions.

Landmark Trials in This Story

Hunder Criteria1990Landmark

The American College of Rheumatology 1990 criteria for the classification of giant cell arteritis

GCA classification: ≥3 of 5 criteria; sensitivity 93.5%, specificity 91.2% versus other vasculitides

Arthritis and rheumatismClassification study
GiACTA2017Landmark

Trial of Tocilizumab in Giant-Cell Arteritis

Sustained glucocorticoid-free remission at 52 weeks: 56% (weekly TCZ) and 53% (q2w TCZ) vs 14% (placebo/26-wk taper) and 18% (placebo/52-wk taper); p<0.001

New England journal of medicineRCTN=251
TABUL2016

The Role of Ultrasound Compared to Biopsy of Temporal Arteries in the Diagnosis and Treatment of Giant Cell Arteritis (TABUL): a diagnostic accuracy and cost-effectiveness study.

Sensitivity for GCA diagnosis (both tests within 10 days of starting treatment): ultrasound 54% (95% CI 48-60%) vs temporal artery biopsy 39% (95% CI 33-46%); specificity 81% (95% CI 73-88%) vs 100% (95% CI 97-100%)

Health Technol AssessProspective multicentre diagnostic accuracy cohort studyN=381
GiACTA Extension2021

Long-term effect of tocilizumab in patients with giant cell arteritis: open-label extension phase of the Giant Cell Arteritis Actemra (GiACTA) trial.

Tocilizumab-free, glucocorticoid-free remission through 2-year part two after stopping weekly tocilizumab in remission at 1 year: 25/59 (42%); median cumulative glucocorticoid dose over 3 years: weekly tocilizumab 2647 mg vs placebo 5277 mg (26-week taper) and 5323 mg (52-week taper) (van Elteren p≤0.001)

Lancet RheumatolOpen-label extension (part two, 2 years) of a randomised controlled trialN=215
Sarilumab GCA phase 32023

A phase 3 randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of sarilumab in patients with giant cell arteritis.

Sustained remission at week 52 (36 patients analysed): sarilumab 200 mg + 26-week taper 6/13 (46%) and 150 mg + 26-week taper 3/7 (43%) vs placebo + 52-week taper 3/10 (30%) and placebo + 26-week taper 0/6 (no p values; authors: clear conclusions difficult)

Arthritis Res TherPhase 3, randomised, double-blind, placebo-controlled trial (terminated early; 83 of 360 planned randomised)N=83
Abatacept GCA withdrawal2017

A Randomized, Double-Blind Trial of Abatacept (CTLA-4Ig) for the Treatment of Giant Cell Arteritis.

Relapse-free survival at 12 months: continued abatacept 48% vs switch to placebo 31% (P=.049)

Arthritis & rheumatology (Hoboken, N.J.)Randomized double-blind withdrawal trialN=41
GCAptAIN2026

Secukinumab for Giant Cell Arteritis.

Sustained remission at 52 weeks: SEC-300/26-week taper 25.6% vs placebo/52-week taper 16.9% (difference 8.7pp, 95% CI −1.3 to 18.8; P=.09)

NEJM evidenceRandomized double-blind phase 3 trial
Mavrilimumab GCA phase 22022

Efficacy and safety of mavrilimumab in giant cell arteritis: a phase 2, randomised, double-blind, placebo-controlled trial.

Time to flare by week 26: mavrilimumab vs placebo HR 0.38 (95% CI 0.15–0.92; P=.026)

Annals of the rheumatic diseasesRandomized double-blind placebo-controlled phase 2 trial

Explore the evidence yourself

Ask AttendMe about any trial, guideline, or clinical question. Evidence-ranked answers from 3.7M+ peer-reviewed articles.

Frequently Asked Questions

How effective is tocilizumab for giant cell arteritis?+
GiACTA randomized 251 patients. Sustained glucocorticoid-free remission at week 52 occurred in 56% with weekly and 53% with every-other-week tocilizumab plus a 26-week prednisone taper, versus 14% and 18% with placebo plus 26-week and 52-week tapers. Median cumulative prednisone doses were 1,862 mg in each tocilizumab group versus 3,296 mg and 3,818 mg, respectively.
Can CRP and ESR be used to monitor GCA during tocilizumab treatment?+
Per EULAR's 2023 imaging update, ultrasound, FDG-PET or MRI may be used in suspected relapse, particularly when laboratory markers are unreliable.

Medical Disclaimer: This content is for educational purposes only and does not constitute medical advice. Clinical decisions should always be based on individual patient assessment, local guidelines, and professional judgement.

All data sourced from published, peer-reviewed articles and clinical practice guidelines.

Claims checked against cited sources: 10 November 2026